Next, in order to know whether regorafenib reduced TGF-β1-induced p-STAT3Tyr705 expression is SHP-1-dependent, we employed siRNA to deplete SHP-1 and found that knockdown of SHP-1 in TGF-β1-treated Hct-116 cells significantly increased both the levels of p-STAT3Tyr705 and mesenchymal markers as well promoting invasive capability, compared with TGF-β1-treated cancer cells (Figure 3B, left panels). The gene discussed is TGFB1; the disease is cancer.